Hypoloc (Nebivolol)

Nebivolol, the active ingredient in Hypoloc, is a beta blocker presented as an oral tablet for oral administration. It selectively blocks β1‑adrenergic receptors and enhances nitric‑oxide mediated vasodilation, thereby lowering elevated blood pressure in adult patients with hypertension.

GNH USA supplies Hypoloc as a licensed, GDP‑compliant international pharmaceutical product. The company serves hospitals, pharmacies, and clinics worldwide, providing reliable sourcing, regulatory support, and logistics for this EU‑origin antihypertensive medication. It ensures compliance with local import regulations and quality standards through dedicated quality assurance teams.

Nebivolol is used to manage hypertension, a condition characterized by chronically elevated arterial pressure.

Essential hypertension: provides sustained reduction of systolic and diastolic blood pressure. Stage 2 hypertension: helps achieve target blood pressure when monotherapy is insufficient. Hypertension in elderly patients: offers effective control with a favorable tolerability profile.

Nebivolol may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Headache - Dizziness - Fatigue

Serious or Rare Side Effects: - Severe bradycardia - Heart block (second‑ or third‑degree) - Allergic reactions, including rash or angioedema

When prescribing Nebivolol, clinicians should consider several safety measures.

Monitor blood pressure: check regularly after initiation and dose changes. Assess heart rate: watch for bradycardia especially in patients with conduction disorders. Avoid abrupt discontinuation: taper under medical supervision to prevent rebound hypertension. Caution in asthma or COPD: β1 selectivity reduces risk but monitor respiratory status. Use with renal or hepatic impairment: dose adjustment may be required. Store at ambient temperature: keep in original packaging, protect from moisture and light.

Nebivolol can interact with other medicines; awareness of the interaction level guides clinical decisions.

Major Interactions (Avoid): - Concurrent use with other β‑blockers: may cause excessive bradycardia and hypotension. - Potent CYP2D6 inhibitors (e.g., paroxetine, fluoxetine): increase nebivolol plasma levels. - Co‑administration with calcium‑channel blockers that affect AV node (e.g., verapamil, diltiazem): risk of severe bradyarrhythmia.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may attenuate antihypertensive effect. - Diuretics: can enhance hypotensive response, monitor volume status. - Alcohol: may increase dizziness and hypotension.